Liver diseases

nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...

SyNTase Gene Editor Corrects Antitrypsin...

CMN Clinical

Oct. 15, 2025

CRISPR Therapeutics has presented preclinical data showing that its investigational therapy CTX460 can correct the SERPINA1 Z (E342K) mutation...

ARCUS Gene Editor Shows Promise Against Hepatitis...

CMN Clinical

Sep. 17, 2025

Precision BioSciences presented encouraging early clinical results from its PBGENE-HBV programme at the 6th International Coalition to Eliminate HBV...

Liver diseases

Liver Transplant, (NCT07053488)
Sponsors:
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

IND Enabling

Phase I

Phase II

Phase III